510(k) Report

510(k) · Cleared

Cleared

JLK-NCCT

K252421510(k) TraditionalCleared Mar 24, 2026235-day reviewClass II21 CFR 892.2080

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

JLK, Inc. · QAS Radiological Computer-Assisted Triage And Notification Software

Cleared on Mar 24, 2026 as substantially equivalent to K222884 (Ischemaview, Inc., 2023) after a 235-day review. Its family tree reaches back 4 generations to 2018.

Decided
Mar 24, 2026
Review
235 days
Class
Class II
Product code
QAS
Recalls
None
Predicates
1

Its longest line of descent runs back 4 generations to DEN170073 (2018). No later device cites it as a predicate yet.

  1. Root · 4 generations backDEN170073 ContaCTViz.Al, Inc. · 2018
  2. 3 generations backK180647 BriefCaseAidoc Medical, Ltd. · 2018
  3. 2 generations backK200855 CINAAvicenna.Ai · 2020
  4. 1 generation backK222884 Rapid NCCT StrokeIschemaview, Inc. · 2023
  5. This deviceK252421 JLK-NCCTJLK, Inc. · 2026
View FIG. 1 as a table

Line of descent and top descendants

GenerationNumberDeviceApplicantDecidedRecalls
−4DEN170073ContaCTViz.Al, Inc.2018—
−3K180647BriefCaseAidoc Medical, Ltd.2018—
−2K200855CINAAvicenna.Ai2020—
−1K222884Rapid NCCT StrokeIschemaview, Inc.2023—
0 (this device)K252421JLK-NCCTJLK, Inc.2026—
FIG. 1 — Lineage of K252421, 2018–2026Source: FDA 510(k) summaries, read by 510(k) Report · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in QAS? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

Top candidate predicates for a new QAS device

  1. #1 K203508 BriefCasescore 25.5 · 4 generations · no Class I recall
  2. #2 Held for the reportin the report
  3. #3 Held for the reportin the report
Get a 510(k) Report

What was it cleared against? (1)

Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.

TypeNumberDeviceApplicantDecidedRecalls
*K222884Rapid NCCT Stroke
Summary page 5
…892.2080  Product Code(s) QAS Legally Marketed Predicate Devices 21 CFR 807.92(a)(3)  Predicate # K222884  Predicate Trade Name Rapid NCCT Stroke  Product Code QAS…
Ischemaview, Inc.2023—

Also cleared against K222884: 3 other devices →

What descends from it?

No later submission names this one as a predicate yet.

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

What does this lineage say?

  • The line of descent spans 8 years and passes through 5 companies; a new generation was cleared every 2.7 years on median.
  • None of the 4 ancestors has a recall.
  • 3 other devices also cite its predicate K222884.

How does its category compare?

All QAS devices

QAS Radiological Computer-Assisted Triage And Notification Software: FDA decisions, review times, recalls and adverse event reports over 20 years. 2026, this device’s year, is highlighted.

FDA decisions per year · QAS

15in 2025

2018: 32019: 52020: 122021: 52022: 152023: 112024: 122025: 152026 (partial year): 11
2007high 15 (2022) · low 0 (2007)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · QAS

101in 2025

2019: 111 days median2020: 112 days median2021: 86 days median2022: 116 days median2023: 98 days median2024: 136 days median2025: 101 days median2026 (partial year): 104 days median
2007high 136 (2024) · low 86 (2021)2026

Receipt to decision; years with fewer than 3 clearances left blank.

Recalls per year · QAS

No recall names QAS since 2007.

Adverse event reports per year · QAS

No MAUDE report names QAS since 2007.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
20070—00
20080—00
20090—00
20100—00
20110—00
20120—00
20130—00
20140—00
20150—00
20160—00
20170—00
20183—00
2019511100
20201211200
202158600
20221511600
2023119800
20241213600
20251510100
2026111040—

What is it indicated for?

JLK-NCCT is a radiological computer-aided triage and notification software designed for analyzing non-contrast head CT (NCCT) images. The software assists hospital networks and trained clinicians by flagging and communicating them of findings suggestive of (1) Intracranial Hemorrhage (ICH) and (2) large vessel occlusion (LVO) involving the internal carotid artery (ICA), middle cerebral artery M1 (MCA-M1) and middle cerebral artery M2 (MCA-M2) on NCCT…

Read the full statement (319 words)

JLK-NCCT is a radiological computer-aided triage and notification software designed for analyzing non-contrast head CT (NCCT) images. The software assists hospital networks and trained clinicians by flagging and communicating them of findings suggestive of (1) Intracranial Hemorrhage (ICH) and (2) large vessel occlusion (LVO) involving the internal carotid artery (ICA), middle cerebral artery M1 (MCA-M1) and middle cerebral artery M2 (MCA-M2) on NCCT images.

JLK-NCCT employs an artificial intelligence (AI) algorithm to analyze images and highlight cases with detected (1) ICH or (2) LVO on an on-premises or cloud-based JLK server. This occurs in parallel with the ongoing standard of care image interpretation. Users receive notifications for cases with suspected ICH and LVO findings via mobile devices. Notifications include compressed preview images for informational purposes only and not intended for diagnostic use beyond notification.

The device does not modify the original medical image, and is not intended to be used as a primary diagnostic device. The results of JLK-NCCT are intended to be used in conjunction with other patient information and professional judgment to assist with triage and prioritization of medical images. Clinicians who receive notifications are responsible for reviewing full images per the standard of care. JLK-NCCT is intended for adults use only.

Limitations and warnings:

• All patients should receive appropriate care, including a CT angiography (CTA) and/or relevant treatments as part of the standard stroke workup. The device is not intended to rule out any medical conditions, therefore, cases without a “Suspected ICH” or "Suspected LVO" notification should not be assumed to exclude ICH or LVO. All cases should undergo a CTA as part of the standard stroke workup.

• The device does not replace the need for CTA or MRA in ischemic stroke workup, it provides workflow prioritization and notification only.

Contraindications/Exclusions:

• Patient Motion: excessive motion leading to artifacts that make the scan technically inadequate.

• Hemorrhagic Transformation

• Very thin or no Ventricles

Indications for use as stated in the FDA summary.

Cite this page

510(k) Report. “K252421: JLK-NCCT.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 6, 2026. https://510kreport.com/device/K252421

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
  • Lineage and recalls computed Nov 3, 2026
  • Page last updated Nov 3, 2026